Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody

被引：8

作者：

Dekhtiarenko, Iryna ^{[1
]}

Lelios, Iva ^{[2
]}

Jacob, Wolfgang ^{[3
]}

Schneider, Meike ^{[2
]}

Weisser, Martin ^{[3
]}

Carlo-Stella, Carmelo ^{[4
,5
]}

Manier, Salomon ^{[6
,7
]}

Harrison, Simon J. ^{[8
]}

Popat, Rakesh ^{[9
]}

Riley, Anna Caroline Hasselbalch ^{[10
]}

Broeke, Ann-Marie E. ^{[3
]}

机构：

[1] Roche Innovat Ctr Zurich, Zurich, Switzerland

[2] Roche Innovat Ctr Basel, Basel, Switzerland

[3] Roche Innovat Ctr Munich, Penzberg, Germany

[4] Humanitas Univ, Milan, Italy

[5] IRCCS Humanitas Res Hosp, Milan, Italy

[6] CHU Lille, Lille, France

[7] Univ Melbourne, Peter MacCallum Canc Ctr, Sir Peter MacCallum Dept Oncol, Melbourne, Australia

[8] Royal Melbourne Hosp, Melbourne, Australia

[9] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England

[10] Rigshosp, Dept Hematol, Copenhagen, Denmark

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177669

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 24 条

[21] An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study
Qin, Ling
Zhong, Yuping
Huang, Dongping
Xie, Haitang
Du, Xin
Liao, Aijun
Zhang, Hongli
Cai, Shengli
Lu, Jin
BLOOD, 2024, 144 : 4736 - 4737
[22] BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor ( CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study
Bal, Susan
Htut, Myo
Nadeem, Omar
Larry, Anderson D., Jr.
Kocoglu, Hakan
Gregory, Tara
Rossi, Adriana C.
Martin, Tom
Egan, Daniel N.
Costa, Luciano
Hu, Hongxiang
Chen, Yanping
Li, Shaoyi
Kelly, Lisa M.
Sarkis, Naomey
Ziyad, Safiyyah
Kao, Wei-Ming
Kaeding, Allison June
Burgess, Michael R.
Berdeja, Jesus G.
BLOOD, 2023, 142
[23] Safety and Preliminary Efficacy of BMS-986393, a GPRC5D CAR T Cell Therapy, in Patients (pts) With Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Results From a Phase 1 Study
Htut, Myo
Nadeem, Omar
Berdeja, Jesus
Anderson, Larry
Rossi, Adriana
Gregory, Tara
Martin, Thomas
Costa, Luciano
Hu, Hongxiang
Mei, Chaoqun
Shrestha, Alok
Ziyad, Safiyyah
Kao, Wei-Ming
Kaeding, Allison
Burgess, Michael
Bal, Susan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S5 - S6
[24] Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
Bal, Susan
Kocoglu, M. Hakan
Nadeem, Omar
Htut, Myo
Gregory, Tara
Anderson, Larry D., Jr.
Costa, Luciano J.
Buchholz, Tonia J.
Ziyad, Safiyyah
Li, Meng
Chen, Yanping
Kaeding, Allison J.
Burgess, Michael R.
Hege, Kristen
Berdeja, Jesus
BLOOD, 2022, 140

← 1 2 3 →